FrancophonIA/ELRC3.0 huggingface dataset:
English: - Atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin (to lower cholesterol levels).
Croatian: REZOLSTA može povećati rizik od nastanka povišenih razina kalija radi drospirenona. - atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin (za snižavanje razina kolesterola).
English: - Buprenorphine/naloxone, methadone (medicines to treat opioid dependence) - Salmeterol (medicine to treat asthma) - Artemether/lumefantrine (a combination medicine to treat malaria) - Dasatinib, irinotecan, nilotinib, vinblastine, vincristine (medicines to treat cancer) - Perphenazine, risperidone, thioridazine (psychiatric medicines) - Clorazepate, diazepam, estazolam, flurazepam (medicines to treat sleeping disorders or anxiety) - Sildenafil, tadalafil, vardenafil (for erectile dysfunction or to treat a heart and lung disorder called pulmonary arterial hypertension) - Glecaprevir/pibrentasvir (to treat hepatitis C infection) - Fesoterodine, solifenacin (to treat urologic disorders).
Croatian: Ako se ne mogu primjenjivati zamjenski lijekovi, potrebno je započeti s primjenom tih lijekova tek nakon medicinske procjene i pod pomnim praćenjem liječnika radi eventualnih nuspojava kortikosteroida. buprenorfin/nalokson, metadon (lijekovi za liječenje ovisnosti o opioidima) - salmeterol (lijek za liječenje astme) - artemeter/lumefantrin (kombinirani lijek za liječenje malarije) - dasatinib, irinotekan, nilotinib, vinblastin, vinkristin (lijekovi za liječenje raka) - perfenazin, risperidon, tioridazin (lijekovi koji se koriste u psihijatriji) - klorazepat, diazepam, estazolam, flurazepam (lijekovi za liječenje poremećaja spavanja ili tjeskobe) - sildenafil, tadalafil, vardenafil (za erektilnu disfunkciju ili za liječenje srčanog i plućnog poremećaja koji se zove plućna arterijska hipertenzija) - glekaprevir/pibrentasvir (za liječenje infekcije hepatitisom C) - fesoterodin, solifenacin (liječenje poremećaja mokraćnog sustava).
English: Therapy with REZOLSTA should not be initiated during pregnancy, and women who become pregnant during therapy with REZOLSTA should be switched to an alternative regimen (see sections 4.2 and 4.4).
Croatian: Liječenje lijekom REZOLSTA ne smije započinjati tijekom trudnoće, a žene koje zatrudne tijekom liječenja lijekom REZOLSTA trebaju prijeći na zamjenski režim (vidjeti dijelove 4.2 i 4.4).
English: Medicinal products that affect darunavir/cobicistat exposure
Croatian: Lijekovi koji utječu na izloženost darunaviru/kobicistatu
English: The combination of rifampicin and REZOLSTA is contraindicated (see section 4.3).
Croatian: Kombinacija rifampicina i lijeka REZOLSTA je kontraindicirana (vidjeti dio 4.3).
English: darunvir/ritonavir 600/100 mg twice daily + OBR N = 296
Croatian: darunvir/ritonavir 600/100 mg dva puta na dan + OOR N = 296
English: Co-administration of REZOLSTA with alfuzosin is contraindicated (see section 4.3).
Croatian: Istodobna primjena lijeka REZOLSTA s alfuzozinom je kontraindicirana (vidjeti dio 4.3).
English: Non-inferiority in virologic response to the darunavir/ritonavir treatment, defined as the percentage of patients with plasma HIV-1 RNA level < 50 copies/mL, was demonstrated (at the pre-defined 12% non-inferiority margin) for both Intent-To-Treat (ITT) and On Protocol (OP) populations in the 48 week analysis.
Croatian: Analiza nakon 48 tjedana pokazala je neinferiornost u virološkom odgovoru na liječenje darunavirom/ritonavirom, definiranu kao postotak bolesnika s razinom u plazmi HIV-1 RNK < 50 kopija/ml (pri unaprijed definiranoj margini neinferiornosti od 12%) i za populaciju namijenjenu za liječenje (engl.
English: Metabolism and nutrition disorders Common anorexia, hypercholesterolaemia, hypertriglyceridaemia
Croatian: Poremećaji metabolizma i prehrane često anoreksija, hiperkolesterolemija, hipertrigliceridemija manje često dijabetes melitus, dislipidemija, hiperglikemija, hiperlipidemija
English: Concomitant use of salmeterol and REZOLSTA is not recommended.
Croatian: Ne preporučuje se istodobna primjena salmeterola i lijeka
English: REZOLSTA and tenofovir disoproxil can be used without dose adjustments.
Croatian: REZOLSTA i tenofovirdizoproksil mogu se uzimati bez prilagodbe doza.
English: Co-administration of REZOLSTA and these anticonvulsants is contraindicated (see section 4.3).
Croatian: Istodobna primjena lijeka REZOLSTA i tih antikonvulziva je kontraindicirana (vidjeti dio 4.3).
English: REZOLSTA and antacids can be used concomitantly without dose adjustment.
Croatian: REZOLSTA i antacidi se mogu uzimati istodobno bez prilagodbe doze.
English: The combination of avanafil and REZOLSTA is contraindicated (see section 4.3).
Croatian: Kombinacija avanafila i lijeka REZOLSTA je kontraindicirana (vidjeti dio 4.3).
English: Co-administration of REZOLSTA and nevirapine is not recommended.
Croatian: Ne preporučuje se istodobna primjena lijeka REZOLSTA i nevirapina.
English: Colloidal silicon dioxide Silicified microcrystalline cellulose Crospovidone
Croatian: Silicijev dioksid, koloidni Celuloza, mikrokristalična, silicirana Krospovidon
English: Based on theoretical considerations co-administration of REZOLSTA with these anticoagulants may increase concentrations of the anticoagulant, which may lead to an increased bleeding risk.
Croatian: Temeljeno na teorijskim postavkama istodobna primjena lijeka REZOLSTA s ovim antikoagulansima može povećati koncentracije antikoagulansa što može povećati rizik od krvarenja. (inhibicija CYP3A i/ili P-glikoproteina)
English: GS-US-216-130 is a single-arm, open-label, Phase III trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of darunavir with cobicistat in 313 HIV-1 infected adult patients (295 treatment-naïve and 18 treatment-experienced).
Croatian: Djelotvornost darunavira od 800 mg jednaput na dan primijenjenog istodobno sa 150 mg kobicistata jedanput na dan u ART-naivnih i ART-iskusnih bolesnika GS-US-216-130 je otvoreno ispitivanje faze III s jednom skupinom koje je procijenilo farmakokinetiku, sigurnost, podnošljivost i djelotvornost darunavira s kobicistatom u 313 HIVom-1 inficiranih odraslih bolesnika (295 prethodno neliječenih i 18 prethodno liječenih).
English: MedDRA system organ class Frequency category
Croatian: Klasifikacija organskih sustava prema MedDRA-i
English: Treatment-naïve darunavir/cobicistat 800/150 mg once daily + emtricitabine/tenofovir disoproxil fumarate N = 363
Croatian: Prethodno neliječeni bolesnici koji su primali darunavir/kobicistat 800/150 mg jedanput na dan + emtricitabin/tenofovirdizoproksilfumarat N = 363
English: Based on theoretical considerations, REZOLSTA is expected to increase the exposure of lomitapide when coadministered.
Croatian: Temeljeno na teorijskim postavkama, očekuje se da će REZOLSTA povećati izloženost lomitapidu kada se primjenjuju istodobno. (CYP3A inhibicija)
English: Co-administration of oral midazolam or triazolam and REZOLSTA is contraindicated (see section 4.3).
Croatian: Istodobna primjena peroralnog midazolama ili triazolama i lijeka REZOLSTA je kontraindicirana (vidjeti dio 4.3).
English: Based on theoretical considerations REZOLSTA is expected to increase these sedative/hypnotic plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama očekuje se da će REZOLSTA povećati koncentracije tih sedativa/hipnotika u plazmi. (CYP3A inhibicija)
English: Based on theoretical considerations REZOLSTA is expected to increase these PDE-5 inhibitor plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama očekuje se da će REZOLSTA povećati koncentracije tih inhibitora PDE-5 u plazmi. (CYP3A inhibicija)
English: HIV-1 RNA < 50 copies/mL mean HIV-1 RNA log change from baseline (log10 copies/mL) CD4+ cell count mean change from baseline
Croatian: HIV-1 RNK < 50 kopija/ml Srednja vrijednost HIV-1 RNK log promjene u odnosu na početnu (log10 kopija/ml)
English: Tell your doctor if you take: - Amlodipine, carvedilol, diltiazem, disopyramide, felodipine, flecainide, lidocaine, metoprolol, mexiletine, nicardipine, nifedipine, propafenone, timolol, verapamil (for heart disease) as the therapeutic effect or side effects of these medicines may be increased.
Croatian: meksiletin, nikardipin, nifedipin, propafenon, timolol, verapamil (za bolest srca) jer se terapijski učinak ili nuspojave tih lijekova mogu pojačati.
English: Combinations with optimised background regimens (OBRs) other than ≥ 2 NRTIs have not been studied in this population.
Croatian: U toj populaciji nisu ispitivane druge kombinacije s optimiziranim osnovnim režimom liječenja (OBR, od engl. optimised background regimen) osim s ≥ 2 NRTI (nukleozidni/nukleotidni inhibitori reverzne transkriptaze, od engl.
English: Based on theoretical considerations nevirapine is expected to decrease darunavir and/or cobicistat plasma concentrations, (CYP3A induction).
Croatian: Temeljeno na teorijskim postavkama očekuje se da će nevirapin sniziti koncentracije darunavira i/ili kobicistata u plazmi (CYP3A indukcija).
English: Based on theoretical considerations REZOLSTA is expected to increase these antifungal plasma concentrations, and darunavir and/or cobicistat plasma concentrations may be increased by the antifungals.
Croatian: Temeljeno na teorijskim postavkama očekuje se da će REZOLSTA povećati koncentracije tih antifungika u plazmi, a antifungici mogu povećati koncentracije darunavira i/ili kobicistata u plazmi. (CYP3A inhibicija i/ili P-gp inhibicija)
English: HIV-1 RNA < 50 copies/mL With Baseline
Croatian: HIV-1 RNK < 50 kopija/ml S početnom HIV-1 RNK (kopija/ml)
English: In these pharmacokinetic trials, the exposure of darunavir 800 mg boosted with cobicistat 150 mg was consistent with that observed when boosted with ritonavir 100 mg. Darunavir as a component of REZOLSTA is bioequivalent to darunavir 800 mg once daily in combination with cobicistat 150 mg once daily co-administered as single medicinal products (see section 5.2).
Croatian: Darunavir je kao komponenta lijeka REZOLSTA bioekvivalentan darunaviru od 800 mg jedanput na dan u kombinaciji s kobicistatom od 150 mg jedanput na dan koji su primijenjeni istodobno kao pojedinačni lijekovi (vidjeti dio 5.2).
English: Based on theoretical considerations REZOLSTA is expected to increase alfentanil plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama očekuje se da će REZOLSTA povećati koncentracije alfentanila u plazmi.
English: Not known toxic epidermal necrolysis*, acute generalised exanthematous pustulosis*
Croatian: nepoznato toksična epidermalna nekroliza*, akutna generalizirana egzantematozna pustuloza* Poremećaji mišićno-koštanog sustava i vezivnog tkiva često mialgija manje često osteonekroza*
English: REZOLSTA 800 mg/150 mg film-coated tablets darunavir/cobicistat
Croatian: REZOLSTA 800 mg/150 mg filmom obložene tablete darunavir/kobicistat
English: Based on theoretical considerations REZOLSTA may alter warfarin plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama REZOLSTA može promijeniti koncentracije varfarina u plazmi.
English: Based on theoretical considerations REZOLSTA may increase methadone plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama REZOLSTA može povećati koncentracije metadona u plazmi.
English: HIV-1 infected patients who were eligible for this trial had a plasma HIV-1 RNA ≥ 1,000 copies/mL.
Croatian: U ispitivanju su mogli sudjelovati bolesnici s infekcijom virusom HIV-1 koji su u plazmi imali ≥ 1000 kopija/ml HIV-1 RNK.
English: Removing the child resistant cap
Croatian: Otvaranje zatvarača sigurnog za djecu
English: REZOLSTA and didanosine can be used without dose adjustments.
Croatian: REZOLSTA se može istodobno primijeniti s didanozinom bez prilagodbe doze.
English: Based on theoretical considerations REZOLSTA is expected to increase metformin plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama očekuje se da će REZOLSTA povećati koncentracije metformina u plazmi.
English: Concomitant use of REZOLSTA with lovastatin and simvastatin is contraindicated (see section 4.3).
Croatian: Istodobna primjena lijeka REZOLSTA s lovastatinom i simvastatinom je kontraindicirana (vidjeti dio 4.3).
English: Low rates of developing resistant HIV-1 virus were observed in ART-naïve patients who are treated for the first time with REZOLSTA or darunavir/ritonavir 800/100 mg once daily in combination with other ART, and in ART-experienced patients with no darunavir RAMs receiving REZOLSTA or darunavir/ritonavir 800/100 mg once daily in combination with other ART.
Croatian: U bolesnika koji prethodno nisu liječeni antiretrovirusnom terapijom (ART) i koji su bili liječeni prvi put lijekom REZOLSTA ili darunavirom/ritonavirom 800/100 mg jednaput na dan u kombinaciji s drugim ART-om i u bolesnika liječenih ART-om bez mutacija povezanih s rezistencijom (RAM) na darunavir koji su primali lijek REZOLSTA ili darunavir/ritonavir 800/100 mg jedanput na dan u kombinaciji s drugim ART-om, bile su zapažene niske stope razvoja rezistentnog HIV-1 virusa.
English: The antiretroviral effect of REZOLSTA is due to the darunavir component.
Croatian: Darunavir uzrokuje antiretroviruski učinak lijeka REZOLSTA.
English: REZOLSTA can be co-administered with H2-receptor antagonists without dose adjustments.
Croatian: H2receptora bez prilagodbe doze.
English: - Bosentan (to treat high blood pressure in the pulmonary circulation) - Buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem, midazolam when used as injection (medicines to treat trouble with sleeping and/or anxiety) - Metformin (to treat type 2 diabetes) - Fentanyl, oxycodone, tramadol (to treat pain).
Croatian: Ako imate oštećenje funkcije bubrega i/ili jetre pogledajte dio „Nemojte kombinirati lijek REZOLSTA ni s jednim od sljedećih lijekova“ - bosentan (za liječenje povišenog krvnog tlaka u plućnom krvotoku) - buspiron, klorazepat, diazepam, estazolam, flurazepam, zolpidem, midazolam kada se koristi u obliku injekcije (lijekovi za liječenje problema sa spavanjem i/ili tjeskobe) - metformin (za liječenje šećerne bolesti tipa 2) - fentanil, oksikodon, tramadol (za liječenje boli).
English: Refer to the Summary of Product Characteristics for PREZISTA for further information.
Croatian: Za više informacija pogledajte sažetak opisa svojstava lijeka za lijek PREZISTA.
English: All subjects darunavir/cobicistat 800/150 mg once daily + OBR N = 313
Croatian: Svi ispitanici darunavir/kobicistat 800/150 mg jedanput na dan + OOR N = 313
English: - Ciclosporin, everolimus, tacrolimus, sirolimus (for dampening down your immune system) as the therapeutic effect or side effects of these medicines might be increased.
Croatian: Liječnik će procijeniti koji način liječenja povišenog kolesterola najbolje odgovara Vašoj specifičnoj situaciji. - ciklosporin, everolimus, takrolimus, sirolimus (za prigušivanje imunološkog sustava) jer se terapijski učinak ili nuspojave tih lijekova mogu pojačati.
English: Outcomes darunvir/ritonavir 800/100 mg once daily + OBR N = 294
Croatian: Ishodi darunvir/ritonavir 800/100 mg jedanput na dan + OOR N = 294
English: Based on theoretical considerations these anticonvulsants are expected to decrease darunavir and/or cobicistat plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama, za te antikonvulzive se očekuje da će smanjiti koncentracije darunavira i/ili kobicistata u plazmi. (CYP3A indukcija).
English: 6/l (see sections 4.2 and 4.4).
Croatian: 6/l (vidjeti dijelove 4.2 i 4.4) ne smiju uzimati lijek REZOLSTA.
English: Among 1,968 treatment-experienced patients receiving darunavir co-administered with ritonavir 600/100 mg twice daily, 236 patients were co-infected with hepatitis B or C. Co-infected patients were more likely to have baseline and treatment emergent hepatic transaminase elevations than those without chronic viral hepatitis (see section 4.4).
Croatian: Od 1968 prethodno liječenih bolesnika, a primali su darunavir primijenjen istodobno s ritonavirom od 600/100 mg dva puta na dan, 236 bolesnika bilo je istodobno inficirano hepatitisom B ili C.
English: REZOLSTA should be used with caution in patients with mild or moderate hepatic impairment (see sections 4.2, 4.3 and 5.2).
Croatian: REZOLSTA se mora s oprezom primjenjivati kod bolesnika s blagim ili umjerenim oštećenjem jetre zbog povišenja koncentracija nevezanog darunavira u plazmi (vidjeti dijelove 4.2, 4.3 i 5.2).
English: Common vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence
Croatian: Poremećaji probavnog sustava vrlo često proljev, mučnina često povraćanje, bol u abdomenu, distenzija abdomena, dispepsija, flatulencija manje često akutni pankreatitis, povišeni enzimi pankreasa
English: darunavir/ ritonavir 800/100 mg once daily N = 343
Croatian: darunavir/ ritonavir 800/100 mg jedanput na dan N = 343
English: At present the effect of raltegravir on darunavir plasma concentrations does not appear to be clinically relevant;
Croatian: Za sada ne postoji klinički značajan učinak raltegravira na koncentracije darunavira u plazmi; REZOLSTA i raltegravir mogu se primijeniti bez prilagodbe doze.
English: Treatment-experienced darunavir/ritonavir 600/100 mg twice daily N = 296
Croatian: Prethodno liječeni darunavir/kobicist at 600/100 mg dva puta na dan N = 296
English: Refer to the Summary of Product Characteristics of other antiretroviral medicinal products for dosing information.
Croatian: Za informacije o doziranju drugih antiretrovirusnih lijekova pogledajte njihov sažetak opisa svojstava lijeka.
English: For more information consult the cobicistat Summary of Product Characteristics.
Croatian: Za više informacija pogledajte sažetak opisa svojstava za kobicistat.
English: Darunavir exposure was shown to be comparable in a bioavailability trial between REZOLSTA and darunavir/ritonavir 800/100 mg q.d.
Croatian: U ispitivanju bioraspoloživosti pokazalo se da je izloženost darunaviru bila usporediva između lijeka REZOLSTA i darunavira/ritonavira od 800/100 mg jedanput na dan u stanju dinamičke ravnoteže i stanju sitosti u zdravih ispitanika.
English: Therapeutic drug monitoring of the immunosuppressive agent must be done when co-administration occurs.
Croatian: Kod istodobne primjene, mora se pratiti terapijski učinak imunosupresivnog lijeka.
English: (most often the lips or the eyes) - severe rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals.
Croatian: Liječnik će Vam objasniti rezultate laboratorijskih testova. - alergijske reakcije poput koprivnjače, teškog oticanja kože i drugih tkiva (najčešće usana ili očiju) - težak osip praćen mjehurima i ljuštenjem kože, osobito oko usta, nosa, očiju i spolnih organa.
English: Co-administration with the following medicinal products due to the potential for loss of therapeutic effect (see section 4.5): - carbamazepine, phenobarbital, phenytoin - rifampicin - lopinavir/ritonavir - St John's wort, (Hypericum perforatum).
Croatian: - karbamazepin, fenobarbital, fenitoin - rifampicin - lopinavir/ritonavir - gospina trava (Hypericum perforatum).
English: Based on theoretical considerations REZOLSTA is expected to increase these beta blocker plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama očekuje se da će REZOLSTA povećati koncentracije tih beta blokatora u plazmi. (CYP3A inhibicija)
English: During the second trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin were 50%,
Croatian: Tijekom drugog tromjesečja trudnoće, Cmax, AUC24h, i Cmin kobicistata bile su 50%, 63% odnosno 83% niže, u usporedbi s postpartalnim razdobljem.
English: Dabigatran, ticagrelor to help stop the clumping of platelets in the treatment of patients with a history of a heart attack
Croatian: avanafil liječenje erektilne disfunkcije dabigatran, tikagrelor pomaže zaustavljanju sljepljivanja krvnih pločica pri liječenju bolesnika koji su u prošlosti imali srčani udar naloksegol liječenje zatvora uzrokovanog opioidima dapoksetin liječenje prijevremene ejakulacije domperidon liječenje mučine i povraćanja
English: To ensure administration of the entire dose of both darunavir and cobicistat, the tablet should be swallowed whole.
Croatian: Tableta se mora progutati cijela, kako bi se osigurala primjena cijele doze i darunavira i kobicistata.
English: Uncommon immune reconstitution inflammatory syndrome
Croatian: manje često upalni sindrom imunološke rekonstitucije
English: The recommended dose of maraviroc is 150 mg twice daily when co-administered with REZOLSTA.
Croatian: Kada se uzima istodobno s lijekom REZOLSTA preporučena doza maraviroka je 150 mg dva puta na dan.
English: Unchanged darunavir accounted for approximately 41.2% and 7.7% of the administered dose in faeces and urine, respectively.
Croatian: 41,2% odnosno 7,7% primijenjene doze darunavira može se naći u stolici, odnosno mokraći u nepromijenjenom obliku.
English: Based on theoretical considerations co-administration of REZOLSTA with dabigatran or ticagrelor may increase concentrations of the anticoagulant.
Croatian: Temeljeno na teorijskim postavkama istodobna primjena lijeka REZOLSTA s dabigatranom ili tikagrelorom može povećati koncentracije antikoagulansa. (inhibicija CYP3A i/ili P-glikoproteina).
English: Outcomes darunavir/ ritonavir 800/100 mg once daily N = 343
Croatian: Ishodi darunavir/ ritonavir 800/100 mg jedanput na dan N = 343
English: Based on theoretical considerations (systemic) dexamethasone is expected to decrease darunavir and/or cobicistat plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama očekuje se da će (sistemski) deksametazon smanjiti koncentracije darunavira i/ili kobicistata u plazmi. (CYP3A indukcija)
English: Treatment-experienced darunavir/cobicistat 800/150 mg once daily + OBR N = 18
Croatian: Prethodno liječeni darunavir/kobicistat 800/150 mg jedanput na dan + OOR N = 18
English: REZOLSTA is expected to increase nevirapine plasma concentrations.
Croatian: Očekuje se da će REZOLSTA povećati koncentracije nevirapina u plazmi (CYP3A inhibicija).
English: Treatment-naïve darunavir/cobicistat 800/150 mg once daily N = 295
Croatian: Prethodno nisu liječeni darunavir/kobi cistat 800/150 mg jedanput na dan N = 295
English: Because of both the potential for HIV transmission and the potential for adverse reactions in breast-fed infants, mothers should be instructed not to breast-feed under any circumstances if they are receiving REZOLSTA.
Croatian: Majke koje primaju lijek REZOLSTA se mora uputiti da ni pod kojim uvjetima ne doje zbog mogućeg prijenosa virusa HIV-a i zbog mogućih nuspojava u dojenčadi.
English: Driving and using machines Do not operate machines or drive if you feel dizzy after taking REZOLSTA.
Croatian: Ako osjetite omaglicu nakon uzimanja lijeka REZOLSTA, nemojte upravljati strojevima i vozilima.
English: Treatment-experienced darunavir/ritonavir 800/100 mg once daily N = 294
Croatian: Prethodno liječeni darunavir/kobicist at 800/100 mg jedanput na dan N = 294
English: Based on theoretical considerations REZOLSTA is expected to increase salmeterol plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama očekuje se da će REZOLSTA povećati koncentracije salmeterola u plazmi. (CYP3A inhibicija)
English: Treatment-experienced darunavir/cobicistat 800/150 mg once daily N = 18
Croatian: Prethodno liječeni darunavir/kobici stat 800/150 mg jedanput na dan N = 18
English: Based on theoretical considerations rifampin is expected to decrease darunavir and/or cobicistat plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama očekuje se da će rifampicin smanjiti koncentracije darunavira i/ili kobicistata u plazmi. (CYP3A indukcija)
English: Treatment-naïve darunavir/cobicistat 800/150 mg once daily + OBR N = 295
Croatian: Prethodno nisu liječeni darunavir/kobicistat 800/150 mg jedanput na dan + OOR N = 295
English: Based on theoretical considerations REZOLSTA is expected to increase concentrations of clonazepam.
Croatian: Temeljeno na teorijskim postavkama očekuje se da će REZOLSTA povećati koncentracije klonazepama. (CYP3A inhibicija)
English: Omeprazole
Croatian: Lomitapid
English: Based on theoretical considerations REZOLSTA may alter norethindrone plasma concentrations.
Croatian: Temeljeno na teorijskim postavkama REZOLSTA može promijeniti koncentracije noretindrona u plazmi. (CYP3A inhibicija, UGT/SULT indukcija)
English: Felodipine
Croatian: Bosentan